Amgen Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2011. For the quarter, the company reported total revenues were $3,973 million against $3,841 million a year ago. Operating income was $1,162 million against $1,068 million a year ago. Adjusted operating income was $1,289 million against $1,306 million a year ago. Net income was $934 million or $1.08 per diluted share against $1,022 million or $1.08 per diluted share a year ago. Adjusted net income was $1,039 million or $1.21 per diluted share against $1,103 million or $1.17 per diluted share a year ago. Capital expenditures for the fourth quarter of 2011 were approximately $241 million versus $182 million in the fourth quarter of 2010. Income before income taxes was $1,051 million compared to $999 million for the same period a year ago. Adjusted income before income taxes was $1,212 million compared to $1,305 million for the same period a year ago. For the year, the company reported total revenues were $15,582 million against $15,053 million a year ago. Operating income was $4,132 million against $5,545 million a year ago. Adjusted operating income was $5,687 million against $6,150 million a year ago. Net income was $3,683 million or $4.04 per diluted share against $4,627 million or $4.79 per diluted share a year ago. Adjusted net income was $4,858 million or $5.33 per diluted share against $5,024 million or $5.21 per diluted share a year ago. Operating cash flow for 2011 decreased 12% to approximately $5.1 billion versus approximately $5.8 billion in 2010 due primarily to increased interest expense and working capital increases related to the launches of Prolia and XGEVA. Capital expenditures were $584 million versus $580 million in 2010. Income before income taxes was $4,150 million compared to $5,317 million for the same period a year ago. Adjusted income before income taxes was $5,668 million compared to $6,188 million for the same period a year ago. GAAP diluted EPS and net income for the full year 2011 were negatively impacted by a previously disclosed charge for a legal settlement. The company provided earnings guidance for the year ending December 31, 2012. The company expects GAAP EPS (diluted) guidance in a range of $5.43 - $5.70 and adjusted EPS (diluted) guidance in a range of $5.90 - $6.15. The company expects total revenue for 2012 to be in the range of $16.1 billion to $16.5 billion. The company expected the adjusted tax rate for 2012 to be in the range of 14% to 15%. Excluding the Puerto Rico excise tax, Amgen expects the adjusted tax rate for 2012 to be in the range of 19% to 20%. The company expects 2012 capital expenditures to be approximately $700 million.